Opsumit and Celecoxib drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Opsumit (macitentan) and Celecoxib (celecoxib). Common drug interactions include arthritis bacterial among females and cough among males.

The phase IV clinical study analyzes what interactions people have when they take Opsumit and Celecoxib. It is created by eHealthMe based on reports of 56 people who take the same drugs from the FDA, and is updated regularly.

What is Opsumit?

Opsumit has active ingredients of macitentan. eHealthMe is studying from 67,926 Opsumit users. Check the latest studies of Opsumit.

What is Celecoxib?

Celecoxib has active ingredients of celecoxib. It is often used in arthritis. eHealthMe is studying from 38,217 Celecoxib users. Check the latest studies of Celecoxib.



On Aug, 09, 2026

56 people who take Opsumit and Celecoxib together, and have interactions are studied.

Opsumit and Celecoxib drug interactions.

What are the common drug interactions of Opsumit and Celecoxib, by gender? *:

female:

  1. Arthritis bacterial (form of joint disorder that involves inflammation of one or more joints due to bacterial infection)
  2. Blood triglycerides increased
  3. Clubbing (deformity of the fingers and fingernails)
  4. Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
  5. Dyspepsia (indigestion)
  6. Dysphagia (a condition in which swallowing is difficult or painful)
  7. Escherichia infection (bacterial infection by escherichia coli)
  8. Flat affect (absence of emotional response to a situation)
  9. Haematocrit decreased
  10. Haemoglobin decreased

male:

  1. Cough
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
  4. Pyrexia (fever)
  5. White blood cell count increased
  6. Arthralgia (joint pain)
  7. Iron deficiency
  8. Lung neoplasm malignant (cancer tumour of lung)
  9. Oxygen consumption decreased
  10. Pneumonia

What are the common drug interactions of Opsumit and Celecoxib, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Arthralgia (joint pain)
  2. Blood pressure decreased
  3. Blood triglycerides increased
  4. Dyspepsia (indigestion)
  5. Dysphagia (a condition in which swallowing is difficult or painful)
  6. Dyspnoea exertional (breathlessness or shortness of breath)
  7. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  8. Insomnia (sleeplessness)
  9. Narcolepsy (brain's inability to regulate sleep-wake cycles normally)
  10. Nausea (feeling of having an urge to vomit)

20-29:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  2. Bronchitis chronic (inflammation of the mucous membrane in the bronchial tubes- chronic)
  3. Gastroenteritis (inflammation of stomach and intestine)
  4. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  5. Ligament sprain (ligament stretched)
  6. Nasopharyngitis (inflammation of the nasopharynx)
  7. Oedema peripheral (superficial swelling)
  8. Palpitations (feelings or sensations that your heart is pounding or racing)
  9. Peripheral swelling
  10. Rhinitis allergic (inflammation of the nasal airways due to allergy)

30-39:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Blood alkaline phosphatase increased
  4. Gamma-glutamyltransferase increased
  5. Heart rate increased
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Oxygen saturation decreased
  8. Pulmonary hypertension (increase in blood pressure in the lung artery)
  9. Respiratory rate decreased (less breathing rate/min)
  10. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

40-49:

  1. Arthralgia (joint pain)
  2. Diarrhoea
  3. Headache (pain in head)
  4. Hypotension (abnormally low blood pressure)
  5. Pulmonary alveolar haemorrhage (acute bleeding)
  6. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  7. Hyperthyroidism (over activity of the thyroid gland)
  8. Arrhythmia (irregular heartbeat)
  9. Chest pain
  10. Cough

50-59:

  1. Pneumonia
  2. Productive cough
  3. Pyrexia (fever)
  4. Right ventricular hypertrophy (right ventricular enlargement)
  5. Arthritis bacterial (form of joint disorder that involves inflammation of one or more joints due to bacterial infection)
  6. Epistaxis (bleed from the nose)
  7. Hot flush (sudden feelings of heat)
  8. Interstitial lung disease
  9. Pulmonary arterial hypertension (high blood pressure in the arteries of lungs)
  10. Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas)

60+:

  1. Headache (pain in head)
  2. Diarrhoea
  3. Abdominal pain
  4. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  5. Aggression
  6. Back pain
  7. Bacteraemia (presence of bacteria in the blood)
  8. Cardiac failure
  9. Cystitis (inflammation of the wall of the bladder)
  10. Drug dependence

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 50 people, 89.29%
  2. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 12 people, 21.43%
  3. Pulmonary Hypertension (increase in blood pressure in the lung artery): 8 people, 14.29%
  4. Cardiac Failure: 8 people, 14.29%
  5. Joint Pain: 7 people, 12.50%
  6. Constipation: 6 people, 10.71%
  7. Asthma: 6 people, 10.71%
  8. Thyroid Diseases: 5 people, 8.93%
  9. Osteoporosis (bones weak and more likely to break): 5 people, 8.93%
  10. Insomnia (sleeplessness): 5 people, 8.93%

* Approximation only. Some reports may have incomplete information.

Do you take Opsumit and Celecoxib?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Opsumit and Celecoxib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Opsumit:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Celecoxib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Opsumit and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Celecoxib and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on macitentan and celecoxib (the active ingredients of Opsumit and Celecoxib, respectively), and Opsumit and Celecoxib (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: